**Group Work**

**Designing a DCE**: PrEP preferences among pregnant and breastfeeding women (PBFW)

**Literature**: Previously reported service and product preferences among pregnant and breastfeeding women (PBFW) include discretion, ease-of-use, reduced dosing and minimal physical discomfort. Developed and proposed long-acting PrEP agents included dapivirine vaginal rings (DVR), long-acting injectables (e.g., cabotegravir (CAB-LA)), new oral ARVs (e.g., islatravir), and arm implants. Additionally, women have shown willingness for multi-purpose prevention technologies (MPTs) currently in development, incorporating both HIV and contraception needs. CAB-LA and DVR for PrEP were approved in South Africa and Botswana in 2022-2023, including in PBFW, but have not been rolled out outside of research programs.

**Research Objective**: Determine preferences for long-acting PrEP and MPTs. Findings are expected to inform product design PrEP service modalities targeting this population

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Attribute** | **Level 1** | **Level 2** | **Level 3** | **Level 4** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |